



Results of Annual General Meeting

Sydney, Australia and San Diego, California (Thursday, 17 May 2018 AEST) – REVA Medical, Inc. (ASX: RVA) (“REVA” or the “Company”) held its Annual General Meeting of Stockholders today and, in accordance with ASX Listing Rule 3.13.2, is pleased to announce that each of the proposals put to stockholders, as set forth in the Proxy Statement dated 6 April 2018, has passed. Please see the attached Proxy Tabulation Report of the voting results.

About REVA Medical

REVA Medical is a medical device company focused on the development and commercialization of bioresorbable polymer technologies for vascular applications. The Company’s lead products are the Fantom and Fantom Encore bioresorbable vascular scaffolds for the treatment of coronary artery disease. REVA is located in San Diego, California, USA and employs over 50 people in the U.S. and Europe.

Fantom, Fantom Encore, and Tyrocore are trademarks of REVA Medical, Inc.

Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions, and expectations and on information currently available to management. All statements that are not statements of historical fact, including those statements that address future operating plans or performance and events or developments that may occur in the future, are forward-looking statements, such as those statements regarding the projections and timing surrounding commercial operations and sales, clinical trials, pipeline product development, and future financings. No undue reliance should be placed on forward-looking statements. Although management believes forward-looking statements are reasonable as and when made, forward-looking statements are subject to a number of risks and uncertainties that may cause actual results to vary materially from those expressed in forward-looking statements, including the risks and uncertainties that are described in the "Risk Factors" section of our Annual Report on Form 10-K filed with the US Securities and Exchange Commission (the "SEC") on March 7, 2018, and as updated in our periodic reports thereafter. Any forward-looking statements in this announcement speak only as of the date when made. REVA does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

**United States
Investor & Media Enquiries:**
REVA Medical, Inc.
Brandi Roberts
Chief Financial Officer
+1 858-966-3003
Cheryl Liberatore
Director, Communications
+1 858-966-3045
ir@teamreva.com

**Australia
Investor Enquiries:**
Inteq Limited
Kim Jacobs
+61 438 217 279
Andrew Cohen
+61 408 333 452

**Australia
Media Enquiries:**
Buchan Consulting
Rebecca Wilson
+61 3 9866 4722

HEAD OFFICE: 5751 Copley Drive, San Diego, CA 92111 • +1 (858) 966-3000 • +1 (858) 966-3099 (FAX) • www.revamedical.com

AUSTRALIAN OFFICE: Suite 4, Level 14, 6 O'Connell Street, Sydney NSW 2000 • +61 2 9237 2800

ARBN 146 505 777 • REVA Medical, Inc., is a foreign company incorporated in Delaware, USA, whose stockholders have limited liability

Proxy Tabulation Report

The stockholders considered 14 proposals at the meeting, each of which is described in more detail in the Company's definitive proxy statement. Of the 41,245,820 shares of the Company's common stock outstanding as of the record date, 28,852,270 shares were represented at the Annual General Meeting. The independent inspector of elections reported the vote of stockholders as set forth below.

1. Election of Directors – The stockholders elected two Class II directors to hold office until the 2021 Annual General Meeting of Stockholders, or until their successors are duly elected and qualified or until their earlier death, resignation, or removal, by the following votes:

Name of Director Elected	For	Withheld	Broker Non-Votes
Robert B. Thomas	28,845,425	6,845	—
C. Raymond Larkin	28,845,425	6,845	—

2. Election of Directors – The stockholders elected one Class I director to hold office until the 2020 Annual General Meeting of Stockholders, or until his successor is duly elected and qualified or until his earlier death, resignation, or removal, by the following votes:

Name of Director Elected	For	Withheld	Broker Non-Votes
Stephen N. Oesterle	28,845,725	6,545	—

The following individuals are continuing directors with terms expiring upon the 2019 Annual General Meeting of Stockholders: Dr. Ross A. Breckenridge and Robert B. Stockman.

The following individuals are continuing directors with terms expiring upon the 2020 Annual General Meeting of Stockholders: Brian H. Dovey and Regina E. Groves.

3. Ratification of Audit Firm – The stockholders ratified the appointment of Grant Thornton LLP to serve as the independent registered public accounting firm for the Company's fiscal year ending December 31, 2018. The proposal was approved by the following vote:

For	Against	Abstain	Broker Non-Votes
28,802,270	—	50,000	—

4. Approval of Issuance of Up to 10% of the Issued Capital of the Company – The stockholders approved the issuance of equity securities of up to an additional 10% of the issued capital of the Company (calculated in accordance with the formula prescribed in ASX Listing Rule 7.1A) on the terms and conditions set forth in the Proxy Statement, which will allow the Company to issue an aggregate of up to 25% of its issued capital without seeking stockholder approval at any time within one year of May 16, 2018, by the following votes:

For	Against	Abstain	Broker Non-Votes
28,809,353	11,533	31,384	—

For personal use only

5. Advisory Vote on Frequency of Stockholder Vote on Executive Compensation – The stockholders approved, on an advisory basis, that an advisory vote on the compensation of named executive officers shall be held at an annual meeting of stockholders every year. The votes were as follows:

<u>Every Year</u>	<u>Every 2 Years</u>	<u>Every 3 Years</u>	<u>Abstain</u>
28,100,714	399,807	351,749	—

6. Advisory Vote on Executive Compensation – The stockholders approved, on an advisory basis, the compensation of the named executive officers for the fiscal year ended December 31, 2017, as set forth in the Proxy Statement, by the following votes:

<u>For</u>	<u>Against</u>	<u>Abstain</u>	<u>Broker Non-Votes</u>
23,006,402	5,781,383	64,485	—

7. Approval of Securities Under the Company’s Amended and Restated 2010 Equity Incentive Plan — The stockholders approved the issuance and transfer of securities under the Company’s Amended and Restated 2010 Equity Incentive Plan (the “Plan”) on the terms and conditions set forth in the Proxy Statement, which will provide that the issue or transfer of securities under the Plan will be excluded from the calculation of the Company’s 15% issue capacity under ASX Listing Rule 7.1, by the following votes, disregarding any votes cast by a Director of the Company or any associate of such Directors:

<u>For</u>	<u>Against</u>	<u>Abstain</u>	<u>Broker Non-Votes</u>
22,981,284	61,533	161,459	—

8. Grant of Stock Options – The stockholders approved the grant of 25,000 options to Dr. Ross A. Breckenridge for the purchase of common stock on the terms and conditions set forth in the Proxy Statement by the following votes, disregarding any votes cast by a Director of the Company or any associate of such Directors:

<u>For</u>	<u>Against</u>	<u>Abstain</u>	<u>Broker Non-Votes</u>
17,389,969	13,472	5,800,835	—

9. Grant of Stock Options – The stockholders approved the grant of 25,000 options to Brian H. Dovey for the purchase of common stock on the terms and conditions set forth in the Proxy Statement by the following votes, disregarding any votes cast by a Director of the Company or any associate of such Directors:

<u>For</u>	<u>Against</u>	<u>Abstain</u>	<u>Broker Non-Votes</u>
17,389,969	5,782,923	31,384	—

10. Grant of Stock Options and Restricted Stock Units – The stockholders approved the grant of 226,000 options and 114,000 restricted stock units to Regina E. Groves for the purchase of common stock on the terms and conditions set forth in the Proxy Statement by the following votes, disregarding any votes cast by a Director of the Company or any associate of such Directors:

For personal use only

For	Against	Abstain	Broker Non-Votes
17,209,894	5,832,923	161,459	—

11. Grant of Stock Options – The stockholders approved the grant of 61,095 options to C. Raymond Larkin for the purchase of common stock on the terms and conditions set forth in the Proxy Statement by the following votes, disregarding any votes cast by a Director of the Company or any associate of such Directors:

For	Against	Abstain	Broker Non-Votes
23,159,726	13,165	31,385	—

12. Grant of Stock Options – The stockholders approved the grant of 86,917 options to Dr. Stephen N. Oesterle for the purchase of common stock on the terms and conditions set forth in the Proxy Statement by the following votes, disregarding any votes cast by a Director of the Company or any associate of such Directors:

For	Against	Abstain	Broker Non-Votes
23,029,651	13,165	161,460	—

13. Grant of Stock Options – The stockholders approved the grant of 25,000 options to Robert B. Stockman for the purchase of common stock on the terms and conditions set forth in the Proxy Statement by the following votes, disregarding any votes cast by a Director of the Company or any associate of such Directors:

For	Against	Abstain	Broker Non-Votes
23,159,726	13,165	31,385	—

14. Grant of Stock Options – The stockholders approved the grant of 25,000 options to Robert B. Thomas for the purchase of common stock on the terms and conditions set forth in the Proxy Statement by the following votes, disregarding any votes cast by a Director of the Company or any associate of such Directors:

For	Against	Abstain	Broker Non-Votes
23,191,110	13,165	1	—

No other items were presented for stockholder approval at the Annual Meeting.